Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.38 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.37 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786666 | 0.92 | PIK3CD (0.65) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1784693 | 0.89 | PIK3CD (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1788989 | 0.82 | PIK3CD (0.70) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL5785803 | 0.82 | PIK3CG (0.70) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL48455 | 0.81 | PIK3CD (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1787255 | 0.81 | PIK3CD (0.69) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL27658380 | 0.81 | PIK3CG (0.68) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1788314 | 0.81 | PIK3CD (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1788182 | 0.80 | PIK3CD (0.77) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1783978 | 0.80 | PIK3CG (0.66) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | claimed |
| US-20120328696-A1 | ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER | HUTECS KOREA PHARMACEUTICAL CO., LTD. (KR) | 2012-12-27 | — | — | US | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| EP-1689391-B1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080261819-A1 | IN VIVO PRODUCTION OF CYCLIC PEPTIDES FOR INHIBITING PROTEIN-PROTEIN INTERACTION | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1689391-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005021519-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | PIK3CG 6/4885PIK3CD 12/4885PIK3CA 1/4885 |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK3 | PIK3CG 6/4885PIK3CD 10/4885PIK3CA 1/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | PIK3CG 23/4885PIK3CD 26/4885PIK3CA 16/4885 |
| US-20120328696-A1 | ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER | SNCA, PARK7, MGAM | PIK3CG 4452/4885PIK3CD 4514/4885PIK3CA 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.